BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
In blow to Lula, Brazil Congress revives controversial environmental bill- What is colostrum? And should you be taking it?
- Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- Far-right AfD invited back to Munich Security Conference in 2026
- 5 Great Crossover Vehicles For Eco-friendliness In 2024
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Far reaching Guide
- 'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank?
- Recalled Super Greens diet supplement powder sickens 45 with salmonella
- Audits of the Top Science fiction Movies This Year
